

## WEST Search History

DATE: Monday, August 16, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L10	L9 and succinamid\$	8
<input type="checkbox"/>	L9	L8 and stroke\$	1314
<input type="checkbox"/>	L8	sulfonamid\$ and (caspase\$ or interleukin\$ or ice or protease)near4(inhibit\$ or antagonist\$)	3269
<input type="checkbox"/>	L7	L6 and (inhibitor\$).ti.	28
<input type="checkbox"/>	L6	L4 and inhibitor\$	97
<input type="checkbox"/>	L5	L4 and succinamid\$	0
<input type="checkbox"/>	L4	L3 and stroke\$	98
<input type="checkbox"/>	L3	l2 and aspart\$	208
<input type="checkbox"/>	L2	L1 and (caspase\$ or interleukin\$ or ice or protease)near4(inhibit\$ or antagonist\$)	488
<input type="checkbox"/>	L1	(warner)near2(lambert\$) or (BASF)near3(aktieng\$)	18974

END OF SEARCH HISTORY

09/274,812

(FILE 'HOME' ENTERED AT 14:24:33 ON 16 AUG 2004)

FILE 'STNGUIDE' ENTERED AT 14:24:43 ON 16 AUG 2004

FILE 'HOME' ENTERED AT 14:24:56 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:25:06 ON 16 AUG 2004

L1 3774 S (AUTOLYSIS?)/TI  
L2 4 S L1 AND (INTERLEUKIN?)/TI

FILE 'STNGUIDE' ENTERED AT 14:25:49 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:32:14 ON 16 AUG 2004

L3 161 S (CAPRATHE, B? OR CAPRATHE B?)/AU,IN  
L4 1565 S (GILMORE, J? OR GILMORE J?)/AU,IN  
L5 154 S (HARTER, W? OR HARTER W?)/AU,IN  
L6 53 S (GALATSI, P? OR GALATSI P?)/AU,IN  
L7 134 S (KOSTLAN, C? OR KOSTLAN C?)/AU,IN  
L8 1996 S L3 OR L4 OR L5 OR L6 OR L7  
L9 54 S (INTERLEUKIN? OR ICE OR CASPASE? OR CYSTEINE? OR PROTEASE?) (3  
L10 30 DUP REM L9 (24 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:36:59 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:37:25 ON 16 AUG 2004

FILE 'STNGUIDE' ENTERED AT 14:39:28 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:39:49 ON 16 AUG 2004

L11 19 S (HOMO) (2A) (VAL OR VAL)  
L12 12 DUP REM L11 (7 DUPLICATES REMOVED)  
L13 10 S L10 AND (BENZENESULFON? OR SULFONAMID? OR BENZENESULPHON?)  
L14 23233 S (BETA) (3A) (AMINO) (2A) (ACID?)  
L15 293 S (INTERLEUKIN? OR ICE OR CASPASE? OR CYSTEINE? OR PROTEASE?) (3  
L16 23 S (INTERLEUKIN? OR ICE OR CASPASE?) (3A) (INHIBIT?) AND L15  
L17 18 DUP REM L16 (5 DUPLICATES REMOVED)

L10 ANSWER 24 OF 30 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
AN 1997:197761 BIOSIS  
DN PREV199799496964  
TI Design, synthesis and SAR of benzenesulfonamide derivatives as  
**inhibitors** of complement C1r **protease** for the treatment  
of inflammatory processes.  
AU Cai, Cuiman; Plummer, Janet S.; Hays, Sheryl J.; **Gilmore, John L.**  
; Emmerling, Mark R.; Wang, Kevin; Jaen, Juan C.  
CS Parke-Davis Pharmaceutical Res. Div., Warner-Lambert Co., 2800 Plymouth  
Road, Ann Arbor, MI 48105, USA  
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3,  
pp. MEDI 87.  
Meeting Info.: 213th National Meeting of the American Chemical Society.  
San Francisco, California, USA. April 13-17, 1997.  
CODEN: ACSRAL. ISSN: 0065-7727.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 2 May 1997  
Last Updated on STN: 2 Jun 1997

=> d ab

L10 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
AB A series of sulfonamides (1) has been prepared as **inhibitors** of  
**interleukin-1 $\beta$**  converting enzyme (ICE), also known as caspase  
1. These compds. were designed to improve potency by rigidifying the  
enzyme bound mol. through an intramol. hydrogen bond. An X-ray crystal  
structure of a representative member of this series bound to the active  
site of ICE, confirms the presence of the hydrogen bonding interaction.

=> d abs

L10 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
AB A series of sulfonamides (1) has been prepared as **inhibitors** of  
**interleukin-1 $\beta$**  converting enzyme (ICE), also known as caspase  
1. These compds. were designed to improve potency by rigidifying the  
enzyme bound mol. through an intramol. hydrogen bond. An X-ray crystal  
structure of a representative member of this series bound to the active  
site of ICE, confirms the presence of the hydrogen bonding interaction.

L10 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1997:161919 CAPLUS  
ED Entered STN: 10 Mar 1997  
TI Design, synthesis and SAR of benzenesulfonamide derivatives as  
**inhibitors** of complement C1r **protease** for the treatment  
of inflammatory processes.  
AU Cai, Cuiman; Plummer, Janet S.; Hays, Sheryl J.; **Gilmore, John L.**  
; Emmerling, Mark R.; Wang, Kevin; Jaen, Juan C.  
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann  
Arbor, MI, 48105, USA  
SO Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17  
(1997), MEDI-087 Publisher: American Chemical Society, Washington, D. C.  
CODEN: 64AOAA  
DT Conference; Meeting Abstract  
LA English  
AB Serine proteases are a group of endopeptidase enzymes that have a serine  
amino acid in their active center. C1r in the complement system is serine  
protease and provides a critical and multifaceted defense system in the host  
defense against infection. Using 2-substituted 4H-3,1-benzoxazin-4-one  
and benzthiazin-4-one as our template, and following a topliss tree anal.,  
we synthesized a series of benzenesulfonamide derivs. as potent C1r  
inhibitors with improved activity. The design, synthesis and structure  
activity relationship of these improved inhibitors will be presented.

L17 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:868699 CAPLUS  
DN 137:370355

TI Preparation of .beta.-amino acid  
arylsulfonamide ether derivatives as inhibitors of  
interleukin-1 $\beta$  converting enzyme

IN Knobelsdorf, James; Hays, Sheryl; Stankovic, Charles J.; Para, Kimberly  
S.; Connolly, Michael K.; Galatsis, Paul; Harter, William; Shahripur,  
Aurash B.; Plummer, Mark Stephen; Lunney, Beth; Janssen, Bernd; Fell, Jay  
Bradford

PA Abbott G.m.b.H. & Co. K.-G., Germany; Warner-Lambert Company; et al.

SO PCT Int. Appl., 214 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089749	A2	20021114	WO 2002-US15002	20020510
	WO 2002089749	A3	20030227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003096826	A1	20030522	US 2002-143675	20020510
	EP 1392280	A2	20040303	EP 2002-734382	20020510
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-289950P	P	20010510		
	WO 2002-US15002	W	20020510		
OS	MARPAT 137:370355				

09/674,812

(FILE 'HOME' ENTERED AT 15:08:27 ON 16 AUG 2004)

FILE 'REGISTRY' ENTERED AT 15:08:42 ON 16 AUG 2004

L1 STRUCTURE UPLOADED

L2 9581 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:10:01 ON 16 AUG 2004


L3 4711 S L2

L4 13 S L3 AND (SULFONYL? OR SULPHONYL?)

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak, Cb, Cy, Hy

G2 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=>

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:262147 CAPLUS  
 DN 130:308784  
 TI Novel fluorescent reporter molecules and their applications including  
 assays for caspases  
 IN Weber, Eckard; Cai, Sui Xiong; Keana, John F. W.; Drewe, John A.; Zhang,  
 Han-Zhong  
 PA Cytovia, Inc., USA  
 SO PCT Int. Appl., 203 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918856	A1	19990422	WO 1998-US21231	19981009
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2308125	AA	19990422	CA 1998-2308125	19981009
	AU 9910722	A1	19990503	AU 1999-10722	19981009
	AU 754634	B2	20021121		
	EP 1026988	A1	20000816	EP 1998-953317	19981009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001519368	T2	20011023	JP 2000-515498	19981009
	NZ 503619	A	20011130	NZ 1998-503619	19981009
	US 6342611	B1	20020129	US 1998-168888	19981009
	BR 9814816	A	20040622	BR 1998-14816	19981009
	US 6335429	B1	20020101	US 2000-521650	20000308
	US 2002150885	A1	20021017	US 2001-947387	20010907
	US 6759207	B2	20040706		
PRAI	US 1997-61582P	P	19971010		
	US 1998-33661	A	19980303		
	US 1998-145746P	P	19980303		
	US 1998-168888	A3	19981009		
	WO 1998-US21231	W	19981009		

OS MARPAT 130:308784  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:487827 CAPLUS  
 DN 122:240452  
 TI Preparation of [[[amidino(phenyl)amino]dioxoalkyl]amino]alkanoates as  
 platelet aggregation inhibitors.  
 IN Bovy, Philippe R.; Rico, Joseph G.; Rogers, Thomas E.; Tjoeng, Foe S.;  
 Zablocki, Jeffery A.  
 PA G.D. Searle and Co., USA; Monsanto Co.  
 SO U.S., 36 pp. Cont.-in-part of U.S. 5,239,113.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5344957	A	19940906	US 1992-953601	19921006
	US 5239113	A	19930824	US 1992-866933	19920410

AT 150302	E	19970415	AT 1992-921348	19921006
ES 2099282	T3	19970516	ES 1992-921348	19921006
EP 542708	A1	19930519	EP 1992-870167	19921014
EP 542708	B1	20010530		
R: PT				
PT 542708	T	20011130	PT 1992-870167	19921014
US 5625093	A	19970429	US 1995-452621	19950525
US 5703125	A	19971230	US 1995-455612	19950531
US 5886208	A	19990323	US 1997-835598	19970410
US 5973003	A	19991026	US 1997-938856	19970926
PRAI US 1991-777811	B2	19911015		
US 1992-866933	A2	19920410		
US 1992-953601	A3	19921006		
US 1994-221913	B2	19940401		
US 1995-452621	A3	19950525		
US 1995-455612	A1	19950531		
OS MARPAT 122:240452				

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:539779 CAPLUS

DN 119:139779

TI Preparation of substituted  $\beta$ -amino acid derivatives useful as platelet aggregation inhibitors

IN Bovy, Philippe Roger; Rico, Joseph Gerace; Rogers, Thomas Edward; Tjoeng, Foe Siong; Zablocki, Jeffery Alan

PA Monsanto Co., USA; G.D. Searle and Co.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307867	A1	19930429	WO 1992-US8512	19921006
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5239113	A	19930824	US 1992-866933	19920410
	AU 9227608	A1	19930521	AU 1992-27608	19921006
	AU 661724	B2	19950803		
	EP 614360	A1	19940914	EP 1992-921348	19921006
	EP 614360	B1	19970319		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07500111	T2	19950105	JP 1993-507711	19921006
	JP 2813462	B2	19981022		
	AT 150302	E	19970415	AT 1992-921348	19921006
	ES 2099282	T3	19970516	ES 1992-921348	19921006
	CA 2115432	C	20030603	CA 1992-2115432	19921006
	EP 542708	A1	19930519	EP 1992-870167	19921014
	EP 542708	B1	20010530		
	R: PT				
	PT 542708	T	20011130	PT 1992-870167	19921014
PRAI	US 1991-777811	A	19911015		
	US 1992-866933	A	19920410		
	WO 1992-US8512	A	19921006		
OS	MARPAT 119:139779				

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:22602 CAPLUS

DN 118:22602

TI Application of arylsulfonyl side-chain protected arginines in solid-phase peptide synthesis based on 9-fluorenylmethoxycarbonyl amino protecting strategy



AU Fischer, Peter M.; Retson, Kim V.; Tyler, Margaret I.; Howden, Merlin E.  
H.  
CS Deakin Res., North Ryde, Australia  
SO International Journal of Peptide & Protein Research (1992), 40(1), 19-24  
CODEN: IJPPC3; ISSN: 0367-8377  
DT Journal  
LA English

=>

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

IT 149727-40-2P 162207-12-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [[[amidinophenyl]amino]dioxoalkyl]amino]alkanoates as platelet aggregation inhibitors)

RN 149727-40-2 CAPLUS


CN Butanoic acid, 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-(hydroxyamino)-4-oxo-, (S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 149727-39-9

CMF C15 H19 N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 162207-12-7 CAPLUS

CN L-Aspartic acid, N-[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 162146-67-0


CMF C15 H18 N4 O6

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 76-05-1

CMF C2 H F3 O2



09/674,812

(FILE 'HOME' ENTERED AT 15:48:23 ON 16 AUG 2004)

FILE 'REGISTRY' ENTERED AT 15:48:43 ON 16 AUG 2004

L1 STRUCTURE UPLOADED

L2 79 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:50:10 ON 16 AUG 2004

L3 4 S L2


FILE 'REGISTRY' ENTERED AT 15:55:21 ON 16 AUG 2004

FILE 'CAPLUS' ENTERED AT 15:55:21 ON 16 AUG 2004

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak, Cb, Cy, Hy

G2 H, Ak

G3 H, Ak


Structure attributes must be viewed using STN Express query preparation.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1998:251152 CAPLUS  
 DN 128:321926  
 TI Preparation of aspartate ester inhibitors of interleukin-1 $\beta$   
 converting enzyme  
 IN Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth Dale; Caprathe,  
 Bradley William; Gilmore, John Lodge; Harter, William Glen; Hays, Sheryl  
 Jeanne; Kostlan, Catherine Rose; Lunney, Elizabeth Ann; Para, Kimberly  
 Suzanne; et al.  
 PA Warner-Lambert Company, USA  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816502	A1	19980423	WO 1997-US18514	19971009
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9749023	A1	19980511	AU 1997-49023	19971009
	AU 738341	B2	20010913		
	EP 932598	A1	19990804	EP 1997-911715	19971009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712530	A	19991019	BR 1997-12530	19971009
	JP 2001506974	T2	20010529	JP 1998-518519	19971009
	NO 9901677	A	19990609	NO 1999-1677	19990409
	KR 2000049048	A	20000725	KR 1999-703117	19990410
PRAI	US 1996-28322P	P	19961011		
	WO 1997-US18514	W	19971009		
OS	MARPAT 128:321926				
RE.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d 4 hitstr


L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 IT 206863-71-0P 206863-77-6P 206863-84-5P  
 206863-88-9P 206864-70-2P 206864-71-3P  
 206865-45-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aspartate ester inhibitors of interleukin-1 $\beta$  converting  
 enzyme)  
 RN 206863-71-0 CAPLUS  
 CN 1-Naphthaleneacetic acid, 3-[(4-amino-2-methyl-1,4-dioxobutyl)amino]-4-  
 carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-77-6 CAPLUS


CN 1-Naphthaleneacetic acid, 3-[[[(2S)-4-amino-2-methyl-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206863-84-5 CAPLUS

CN 1-Naphthaleneacetic acid, 3-[(4-amino-1,4-dioxobutyl)amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-88-9 CAPLUS


CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-70-2 CAPLUS


CN 1-Naphthaleneacetic acid, 3-[[ (2S)-4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206864-71-3 CAPLUS

CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-(1-methylethyl)-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206865-45-4 CAPLUS

CN 1-Naphthaleneacetic acid, 3-[[4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

CN 1-Naphthaleneacetic acid, 5-(1,1-dimethylethoxy)-3-[[2-methyl-1,4-dioxo-4-  
[(2-phenylethyl)amino]butyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX  
NAME)






RN 206865-29-4 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(phenylmethoxy)amino]butyl]amino]-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206865-30-7 CAPLUS

CN 1-Naphthaleneacetic acid, 3-[[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(phenylmethoxy)amino]butyl]amino]-2,5-dioxo-5-(phenylmethoxy)pentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>